Susquehanna Fundamental Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-514,379	Closed	-$4.55M	–	862
2023 Q1	$4.55M	Sell	514,379 -138,395	-21%	-$1.37M	0.11%	237
2022 Q4	$5.95M	Buy	652,774 +203,000	+45%	+$1.77M	0.1%	254
2022 Q3	$3.63M	Buy	+449,774	New	+$3.98M	0.06%	404
2022 Q1	$3.19M	Sell	340,153 -256,272	-43%	-$2.14M	0.06%	422
2021 Q4	$4.78M	Buy	596,425 +392,466	+192%	+$3.54M	0.13%	206
2021 Q3	$1.99M	Sell	203,959 -167,724	-45%	-$1.57M	0.04%	602
2021 Q2	$3.68M	Sell	371,683 -255,737	-41%	-$2.71M	0.07%	396
2021 Q1	$7.24M	Sell	627,420 -512,923	-45%	-$5.88M	0.12%	223
2020 Q4	$11M	Buy	1,140,343 +596,332	+110%	+$5.71M	0.2%	131
2020 Q3	$4.9M	Buy	544,011 +203,811	+60%	+$2.16M	0.15%	196
2020 Q2	$4.2M	Buy	+340,200	New	+$3.85M	0.2%	128
2019 Q1	–	Sell	-265,845	Closed	-$4.1M	–	431
2018 Q4	$4.1M	Sell	265,845 -103,400	-28%	-$2.12M	0.72%	37
2018 Q3	$7.95M	Sell	369,245 -60,500	-14%	-$1.4M	1.35%	10
2018 Q2	$10.5M	Buy	429,745 +73,300	+21%	+$1.49M	1.55%	3
2018 Q1	$6.09M	Buy	+356,445	New	+$6.96M	0.72%	19

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna Fundamental Investments's TEVA Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 514,379 shares — an estimated $4.55M sold.

Susquehanna Fundamental Investments first reported a position in TEVA in Q1 2018 and held it in 15 quarters. The position peaked at $11M in Q4 2020. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 514,379 Teva Pharmaceuticals shares in Q2 2023, an estimated $4.55M.
Susquehanna Fundamental Investments first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 15 quarters.
Susquehanna Fundamental Investments's Teva Pharmaceuticals position peaked at $11M in Q4 2020.
428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.